Zynerba Pharmaceuticals Reports Second Quarter 2019 Financial Results and Operational Highlights

DEVON, PA — Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, reported financial results for the second quarter ended June 30, 2019 and provided an overview of recent operational highlights.

“The past few months have been very productive for our team,” said Armando Anido, Chairman and Chief Executive Officer of Zynerba. “We initiated new studies in autism spectrum disorder and 22q11.2 deletion syndrome, obtained Fast Track Designation for Zygel™ in FXS, enhanced our senior management team with two excellent additions in Medical and Regulatory, received an important new patent for CBD, and were added to the Russell 2000® and 3000® indices. We also extended our cash runway into the second half of 2021 through the addition of $27.0 million in cash from our ATM in the second quarter and a positive decision from the Australian government that will provide

... read more at: https://mychesco.com/a/news/business/finance/zynerba-pharmaceuticals-reports-second-quarter-2019-financial-results-and-operational-highlights/


Leave a Reply